For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Nexstar Pharmaceuticals, Inc.

USPTO Granted Patents = 131

CIPO Patents = 1

Trademarks = 1

Forward Citations = 7,419

Loading Chart...

Loading Chart...

86 inventors (with patents filed for the assignee):

Larry M Gold (91 out of 191 patents)

Sumedha D Jayasena (20 out of 27 patents)

Nebojsa Janjic (17 out of 70 patents)

4. Bruce Eaton (14 out of 36 patents)

5. Kirk B Jensen (11 out of 14 patents)

6. Diane Tasset (10 out of 10 patents)

7. Craig Tuerk (9 out of 18 patents)

8. Karl Y Hostetler (8 out of 71 patents)

9. Andrew Stephens (8 out of 11 patents)

10. Gary P Kirschenheuter (7 out of 19 patents)

11. Jill P Adler-Moore (7 out of 10 patents)

12. Drew Smith (6 out of 9 patents)

13. Su-Ming Chiang (6 out of 10 patents)

14. Nikos C Pagratis (6 out of 14 patents)

15. Chi Tu (5 out of 8 patents)

Core Competencies:

Antiviral Liponucleosides

Nucleic Acid Ligands

High Affinity Oligonucleotide Ligands

Vascular Endothelial Growth Factor

Nucleoside Modifications

Tumor Targeting

Systematic Evolution of Ligands

DNA Polymerase Inhibitors

Thrombin Ligands

Homogeneous Detection

Palladium Catalyzed Methods

Therapeutic Agents

131 patents: Sort by Forward Citations

1. 6252060 - Antiviral liponucleosides: treatment of hepatitis B (2001-06-26),

2. 6207816 - High affinity oligonucleotide ligands to growth factors (2001-03-27),

3. 6184364 - High affinity nucleic acid ligands containing modified nucleotides (2001-02-06),

4. 6183967 - Nucleic acid ligand inhibitors to DNA polymerases (2001-02-06),

5. 6177557 - High affinity ligands of basic fibroblast growth factor and thrombin (2001-01-23),

6. 6177555 - Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction (2001-01-23),

7. 6171795 - Nucleic acid ligands to CD40ligand (2001-01-09),

8. 6168778 - Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes (2001-01-02),

9. 6147204 - Nucleic acid ligand complexes (2000-11-14),

10. 6143882 - Urea nucleosides as therapeutic and diagnostic agents (2000-11-07),

11. 6140490 - High affinity nucleic acid ligands of complement system proteins (2000-10-31),

12. 6127119 - Nucleic acid ligands of tissue target (2000-10-03),

13. 6124449 - High affinity TGF.beta. nucleic acid ligands and inhibitors (2000-09-26),

14. 6120800 - Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting (2000-09-19),

15. 6114120 - Systematic evolution of ligands by exponential enrichment: tissue selex (2000-09-05),

NeXstar Pharmaceuticals, Inc. is a leading biopharmaceutical company specializing in the research, development, and commercialization of innovative therapeutics for various diseases. With a strong focus on advancing scientific discoveries, NeXstar employs cutting-edge technologies to address unmet medical needs. The company is committed to improving patient outcomes and enhancing the quality of life for individuals worldwide. Visit our website to learn more about our groundbreaking medical discoveries and ongoing clinical trials.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

131 Patents

#6 in Boulder, CO

#51 in Colorado

#2,838 in US

#5,960 in the World

Boulder, CO, United States of America

Nexstar Pharmaceuticals, Inc.

Forward Citations = 7,419

86 inventors:

Larry M Gold (91 out of 191 patents)

Sumedha D Jayasena (20 out of 27 patents)

Nebojsa Janjic (17 out of 70 patents)

4. Bruce Eaton (14 out of 36 patents)

5. Kirk B Jensen (11 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…